BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:12 PM
 | 
Nov 18, 2009
 |  BC Extra  |  Company News

FDA panel rebuffs Xolair for children

An FDA panel voted 10-4 on Wednesday that data for Xolair omalizumab from Genentech Inc. and Novartis AG (NYSE:NVS; SIX:NOVN) do not support its approval to treat...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >